PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Hyundai Pharm Co., Ltd.

USPTO PatentsView assignee record - 7 granted patents across 5 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Hyundai ranks #35,788 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 5 technology areas.

#35,788
of 49,997 US assignees by volume
11th percentile
by Innovation Score (22.7/100)
12.7
avg claims per patent
-50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R35788 · Foreign Corporation #35,788 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 7 grants
  • MID-PACK #35,788/49,997
  • PHOTO-FINISH Hydrovaze
  • CPC-NARROW A61P · 5 areas
  • INNOV-THIN 22.7/100
  • CLAIMS-RICH 12.7 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -50% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Hydrovaze LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Hyundai’s 22.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Hyundai

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Hyundai's Innovation Score is 22.7/100 (11th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Hyundai?

Each dot is one of Hyundai’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Hyundai’s own 12.7 claims/patent is at or below the 13.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Hyundai vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 6.97.07.077.07.07.1 0510152025 Granted patents (volume) Avg claims / patent Hydrovaze LLC - 7, 13.57HydrovazeHyduro, Inc. - 7, 5.86HyduroHyndai Motor Company - 7, 11Hyndai MotorHypower Microelectronics (Wuxi) Co., Ltd. - 7, 15.29Hypower Microelec…I-Tech Machine Tool Inc. - 7, 1I-tech Machine To…I2X GMBH - 7, 18.43I2XIBM International Group BV - 7, 17.14IBM International…ICE Data Pricing & Reference Data, LLC - 7, 22ICE Data Pricing…Hyundai Pharm Co., Ltd. - 7, 12.71Hyundai Pharm
Hyundai vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Hyundai's grants concentrate

Hyundai Pharm Co., Ltd. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2015. By volume, Hyundai sits between Hydrovaze LLC and ICE Data Pricing & Reference Data, LLC.

Who files at Hyundai's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Hyundai holds 7 patents at rank #35,780, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Hyundai

By rank, the assignees closest to #35,780 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Hyundai's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Hyundai, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Hyundai ranks #2,588 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (23 here).

Chase Pharmaceuticals Corporation 23 Pacific Scientific Energetic Materials Company (Arizona) LLC 23 Guangdong Bestek E-commerce Co., Ltd. 23 Anko Food Machine Co., Ltd. 23

Hyundai's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

23 11th percentile higher than 11% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 201520172018201920202025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Hyundai Pharm Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 14.3%
2017 1 14.3%
2018 1 14.3%
2019 1 14.3%
2020 2 28.6%
2025partial year 1 14.3%

Which technologies does Hyundai Pharm Co., Ltd. patent most?

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Hyundai Pharm Co., Ltd.'s patent record in context - here's where to go next.

  • Hyundai Pharm Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #35,788 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Hyundai Pharm Co., Ltd. against Hydrovaze LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 22.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.